X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Linagliptin is a DPP-4 inhibitor (gliptin) used to treat type 2 diabetes. Unlike most diabetes tablets, it is hardly excreted via the kidneys and therefore does not need adjusting when kidney function is impaired. It lowers blood sugar moderately, rarely causes hypoglycaemia on its own and is weight-neutral — but it does not protect the heart and kidneys the way SGLT2 inhibitors do.
See more detail.gif)
Linagliptin has comparatively few relevant interactions. In studies with metformin, simvastatin, digoxin or warfarin, no clinically significant changes were seen.¹ The important points concern two mechanisms: partners that also lower blood sugar, and agents that speed up the breakdown of linagliptin.
| Combination | Consequence | What to do |
|---|---|---|
| Sulfonylureas such as glimepiride | Markedly increased risk of hypoglycaemia | The sulfonylurea dose may be lowered; measure blood sugar, know the warning signs |
| Insulin | Increased risk of hypoglycaemia | The insulin dose may be adjusted; discuss a measuring plan |
| Strong enzyme inducers such as rifampicin, carbamazepine, phenytoin | Linagliptin is broken down faster, and the effect can weaken | Watch blood sugar and HbA1c; a different diabetes medicine if needed |
| St John's wort | As above: faster breakdown, weaker effect | Do not add it without checking first |
| ACE inhibitors such as ramipril | An increased risk of angioedema is being discussed for the drug class | The combination is common; know the warning signs of swelling |
| Cortisone, e.g. prednisolone | Blood sugar rises, masking the effect | Monitor blood sugar more closely during high-dose cortisone courses |
| Beta blockers | Can blunt the warning signs of hypoglycaemia (only relevant with a sulfonylurea or insulin) | Watch for atypical signs such as sweating and confusion |
| Alcohol | Delayed hypoglycaemia with a sulfonylurea or insulin; puts a strain on the pancreas | Restraint; see medications and alcohol |
The inducer trap. Linagliptin is handled by transport proteins and liver enzymes that certain active ingredients can "rev up". According to the SmPC, its efficacy may then be reduced.¹ The tricky part: nothing acute happens. Blood sugar creeps up, and at the next HbA1c value an increase in the dose of other medicines is considered, even though an interaction is actually behind it. Herbal St John's wort is particularly easy to overlook — why "herbal" does not mean "harmless" is shown in the guide herbal medicines.
The combination creates the risk. Linagliptin on its own hardly ever leads to hypoglycaemia. But it rarely stands alone on a medication plan. As soon as a sulfonylurea or insulin is added, the risk of hypoglycaemia is real — and even higher in older age, with irregular meals or after alcohol. Check your combination in the interaction check of the brite app and keep your medication plan up to date so that the hospital, dental practice and pharmacy also know what you take.
According to the German National Disease Management Guideline, type 2 diabetes is first treated with lifestyle changes, usually supplemented with metformin. If there is existing cardiovascular or kidney disease, an SGLT2 inhibitor or a GLP-1 receptor agonist is added early, because a benefit on hard endpoints has been shown for these groups. DPP-4 inhibitors are one of several further options when the target value is not reached or other medicines are not suitable.²,³
| Active ingredient (class) | Blood sugar lowering | Weight | Hypoglycaemia (alone) | Proven heart/kidney protection |
|---|---|---|---|---|
| Linagliptin | Moderate | Neutral | Rare | No (safe, but neutral) |
| Sitagliptin | Moderate | Neutral | Rare | No (safe, but neutral) |
| Metformin | Good | Neutral to slightly lowering | Rare | Long-standing baseline treatment |
| SGLT2 inhibitors | Moderate, lower with weak kidneys | Slightly lowering | Rare | Yes, for heart failure and kidneys |
| GLP-1 receptor agonists such as liraglutide | Good to strong | Markedly lowering | Rare | Yes, for certain active ingredients |
| Sulfonylureas | Good | Tends to increase | Common | No |
A direct comparison with the sulfonylurea glimepiride (the CAROLINA trial) showed similar cardiovascular safety but markedly fewer episodes of hypoglycaemia on linagliptin.¹ This is exactly where its niche lies: people for whom hypoglycaemia would be particularly dangerous — for example in older age with a risk of falls — who can no longer take metformin because of their kidneys and for whom an injection is not wanted or not possible.
Linagliptin has been approved throughout the EU since 2011. In Germany, the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), the body that decides what statutory health insurance covers, found no added benefit over the appropriate comparator therapy in its early benefit assessment under the Pharmaceuticals Market Reorganisation Act (AMNOG). In connection with this assessment, the original manufacturer decided not to market the drug regularly in Germany.⁵ This is a decision about price and reimbursement, not a safety warning.
In practice this means: if linagliptin is prescribed — often in nephrology or for people on dialysis — it frequently comes as an individual import from another EU country. As patent protection expires, generics may be added. Your pharmacy will clarify whether a product is currently available for you and how your health insurance covers the costs. If supply is uncertain, talk about a plan B early — a break in supply is not an emergency for a diabetes tablet, but it should not only come to light on the last day of the pack. Background in the guide medication shortages.
There is only limited experience with DPP-4 inhibitors in pregnancy. According to the SmPC, the use of linagliptin in pregnancy should be avoided as a precaution; during breastfeeding, breastfeeding and treatment have to be weighed against each other, because a risk to the child cannot be ruled out.¹ The medicine of choice for diabetes that needs treatment in pregnancy is insulin. If you want to become pregnant, raise this early — the switch should ideally happen before the pregnancy. An independent assessment is provided by Embryotox, the advisory centre at the Charité in Berlin.⁶
No dose adjustment is intended. The low risk of hypoglycaemia and the absence of any kidney adjustment make linagliptin attractive in older age. At the same time, the number of medicines rises with age — and with it the likelihood that a sulfonylurea, a beta blocker or a cortisone preparation changes the equation. The guide medications in old age gives you your bearings.
According to the SmPC, no adjustment is intended with impaired liver function either; with severe liver impairment, however, experience is limited. As type 2 diabetes often goes hand in hand with fatty liver, it is worth keeping track of liver values over time.
Linagliptin itself usually does not need to be paused for safety reasons before procedures. Things are different with metformin and SGLT2 inhibitors — and therefore also with fixed-dose combinations that contain these partners. Before any operation, clarify with the anaesthesia team what is left out and when, and bring your medication plan. More on this under medications before surgery. If you are trying intermittent fasting, you will find tips on dosing windows in the guide medications and intermittent fasting — important above all for combinations with sulfonylureas or insulin.
Half true. Linagliptin is well tolerated by your kidneys — the dose does not have to be adjusted, and it does not build up when kidney function declines. That does not mean it protects the kidneys: in the large safety trial, linagliptin showed no advantage over placebo on hard kidney endpoints such as needing dialysis. When your practice says "good for the kidneys", it usually means exactly this simplicity. Feel free to ask whether a kidney-protective medicine such as an SGLT2 inhibitor might also be an option for you — sometimes there are good reasons against it, sometimes it simply has not been discussed yet.
This is the most common feedback, and it is completely normal. Linagliptin does not change any physical state you can feel; it improves the insulin response to meals in the background. Only long-term blood sugar after about three months shows whether that is enough. Honest expectations matter too: the drop is moderate. If you start with a markedly raised baseline value, linagliptin alone will often not get you to the target. That is then not a failure of the medicine, nor yours, but a reason to rethink the treatment plan together. Leaving the tablet out on your own because you "don't notice anything", on the other hand, is the worst solution.
Usually because of the kidneys. Sitagliptin works in the same way but has to be reduced when kidney function is impaired, and with fluctuating kidney values — for example around dialysis — a fixed dose is more practical. Because linagliptin is not regularly marketed in Germany, the pharmacy then orders it as an import. What matters for you is reordering in good time, because imports can take longer than a standard prescription. A reminder a few days before the pack runs out saves you the shortfall.
On its own only rarely, because the effect is linked to raised blood sugar. But the question is almost always: what else are you taking? With a sulfonylurea or insulin, hypoglycaemia is common, especially after skipped meals, unaccustomed exercise or after alcohol. Know your personal warning signs, carry glucose tablets with you and note episodes of hypoglycaemia with the time and circumstances — that helps the practice more than a vague "sometimes I feel shaky".
The interaction check reviews your whole list — not just the diabetes tablet.
